表紙
市場調查報告書

睡眠障礙治療藥的開發平台分析

Sleep Disorders Drug Development Pipeline Review, 2017

出版商 GlobalData 商品編碼 564941
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
睡眠障礙治療藥的開發平台分析 Sleep Disorders Drug Development Pipeline Review, 2017
出版日期: 2017年09月26日內容資訊: 英文 76 Pages
簡介

本報告提供各種睡眠障礙 (不寧腿症候群·夜間頻尿·失眠症)的治療藥臨床實驗·開發趨勢相關分析,提供疾病概要,迄今治療藥的開發·上市情形,現在臨床實驗中/審查中的主要開發中產品一覽,暫停中·已中止計劃的概要,今後臨床實驗的方向性和實現預測等相關調查。

第1章 目錄

第2章 簡介

  • 分析範圍
  • 不寧腿症候群:概要
  • 夜間頻尿:概要
  • 失眠症:概要

第3章 治療藥的開發

  • 不寧腿症候群 (不寧腿症候群,)
  • 夜間頻尿 (夜間多尿症)
  • 失眠症

第4章 治療藥的評估

  • 不寧腿症候群
  • 夜間頻尿
  • 失眠症

第5章 參與治療藥開發的的企業

  • 不寧腿症候群
  • 夜間頻尿
  • 失眠症

第6章 現在暫停中的計劃

  • 不寧腿症候群
  • 夜間頻尿
  • 失眠症

第7章 開發中止的計劃

  • 不寧腿症候群
  • 失眠症

第8章 產品開發的里程碑

  • 不寧腿症候群
  • 夜間頻尿
  • 失眠症

第9章 附錄

圖表一覽

目錄
Product Code: GBIHC022IDB

Executive Summary:

Restless legs syndrome is characterized by a distressing, irresistible need or urge to move the legs. There are a total of eight products in development for this indication, by eight companies. Key companies operating in this pipeline space include Mundipharma International and Galenica.

Nocturia describes the excessive urination at night. There are a total of eight products in development for this indication, by six companies. Key companies operating in this pipeline space include Ferring International and Sanwa Kagaku Kenkyusho.

Finally, Insomnia is a serious sleeping disorder characterized by the inability to fall or stay asleep. There are a total of 31 products in development for this indication, by 27 companies and three academic institutions. Key companies operating in this pipeline space include Johnson & Johnson, Merck and Overseas Pharmaceuticals.

Across all three of these indications there is a diverse range of molecular targets due to the different pathologies of the indications. The most common targets for restless legs syndrome, nocturia and insomnia therapeutics are D2 dopamine receptor, vasopressin V2 receptor and orexin receptor, respectively.

The report,"Sleep Disorders Drug Development Pipeline Review, 2017" provides an overview of the sleep disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Restless Legs Syndrome, Nocturia and Insomnia and features dormant and discontinued projects.

Scope:

  • Which companies are the most active within the pipeline for sleep disorder therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of sleep disorders?

Reasons to buy:

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Sleep Disorders Report Coverage
  • 2.2. Restless Legs Syndrome. Overview
  • 2.3. Nocturia. Overview
  • 2.4. Insomnia. Overview

3. Therapeutics Development

  • 3.1. Restless Legs Syndrome
  • 3.2. Nocturia
  • 3.3. Insomnia

4. Therapeutics Assessment

  • 4.1. Restless Legs Syndrome
  • 4.2. Nocturia
  • 4.3. Insomnia

5. Companies Involved in Therapeutics Development

  • 5.1. Restless Legs Syndrome
  • 5.2. Nocturia
  • 5.3. Insomnia

6. Dormant Projects

  • 6.1. Restless Legs Syndrome
  • 6.2. Nocturia
  • 6.3. Insomnia

7. Discontinued Products

  • 7.1. Restless Legs Syndrome
  • 7.2. Insomnia

8. Product Development Milestones

  • 8.1. Restless Legs Syndrome
  • 8.2. Nocturia
  • 8.3. Insomnia

9. Appendix

  • 9.1. Methodology
  • 9.2. Coverage
  • 9.3. Secondary Research
  • 9.4. Primary Research
  • 9.5. Expert Panel Validation
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Restless Legs Syndrome
  • Table 2: Number of Products under Development by Companies Restless Legs Syndrome
  • Table 3: Products under Development by Companies Restless Legs Syndrome
  • Table 4: Number of Products under Development for Nocturia
  • Table 5: Number of Products under Development by Companies Nocturia
  • Table 6: Products under Development by Companies Nocturia
  • Table 7: Number of Products under Development for Insomnia
  • Table 8: Number of Products under Development by Companies Insomnia
  • Table 9: Number of Products under Development by Universities/Institutes Insomnia
  • Table 10: Products under Development by Companies Insomnia
  • Table 11: Products under Development by Universities/Institutes Insomnia
  • Table 12: Number of Products by Stage and Target Restless Legs Syndrome
  • Table 13: Number of Products by Stage and Mechanism of Action Restless Legs Syndrome
  • Table 14: Number of Products by Stage and Route of Administration Restless Legs Syndrome
  • Table 15: Number of Products by Stage and Molecule Type Restless Legs Syndrome
  • Table 16: Number of Products by Stage and Target Nocturia
  • Table 17: Number of Products by Stage and Mechanism of Action Nocturia
  • Table 18: Number of Products by Stage and Route of Administration Nocturia
  • Table 19: Number of Products by Stage and Molecule Type Nocturia
  • Table 20: Number of Products by Stage and Target Insomnia
  • Table 21: Number of Products by Stage and Mechanism of Action Insomnia
  • Table 22: Number of Products by Stage and Route of Administration Insomnia
  • Table 23: Number of Products by Stage and Molecule Type Insomnia
  • Table 24: Restless Legs Syndrome - Pipeline by Galenica Ltd
  • Table 25: Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co Inc
  • Table 26: Restless Legs Syndrome - Pipeline by Merz Pharma GmbH & Co KgaA
  • Table 27: Restless Legs Syndrome - Pipeline by Mundipharma International Ltd
  • Table 28: Restless Legs Syndrome - Pipeline by Omeros Corp
  • Table 29: Restless Legs Syndrome - Pipeline by Serina Therapeutics Inc
  • Table 30: Nocturia - Pipeline by Astellas Pharma Inc
  • Table 31: Nocturia - Pipeline by Ferring International Center SA
  • Table 32: Nocturia - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd
  • Table 33: Nocturia - Pipeline by Vantia Therapeutics
  • Table 34: Insomnia - Pipeline by Alexza Pharmaceuticals Inc
  • Table 35: Insomnia - Pipeline by Athenex Inc
  • Table 36: Insomnia - Pipeline by Eisai Co Ltd
  • Table 37: Insomnia - Pipeline by Evotec AG
  • Table 38: Insomnia - Pipeline by Grupo Ferrer Internacional SA
  • Table 39: Insomnia - Pipeline by Heptares Therapeutics Ltd
  • Table 40: Insomnia - Pipeline by Idorsia Ltd
  • Table 41: Insomnia - Pipeline by Intec Pharma Ltd
  • Table 42: Insomnia - Pipeline by Intra-Cellular Therapies Inc
  • Table 43: Insomnia - Pipeline by Johnson & Johnson
  • Table 44: Insomnia - Pipeline by Leading BioSciences Inc
  • Table 45: Insomnia - Pipeline by Merck & Co Inc
  • Table 46: Insomnia - Pipeline by Neurim Pharmaceuticals Ltd
  • Table 47: Insomnia - Pipeline by Reviva Pharmaceuticals Inc
  • Table 48: Insomnia - Pipeline by Shionogi & Co Ltd
  • Table 49: Insomnia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd
  • Table 50: Insomnia - Pipeline by Yangtze River Pharmaceutical Group
  • Table 51: Restless Legs Syndrome - Dormant Projects
  • Table 52: Nocturia - Dormant Projects
  • Table 53: Insomnia - Dormant Projects
  • Table 54: Restless Legs Syndrome - Discontinued Products
  • Table 55: Insomnia - Discontinued Products

List of Figures

  • Figure 1: Number of Products under Development for Restless Legs Syndrome
  • Figure 2: Number of Products under Development by Companies Restless Legs Syndrome
  • Figure 3: Number of Products under Development for Nocturia
  • Figure 4: Number of Products under Development by Companies Nocturia
  • Figure 5: Number of Products under Development for Insomnia
  • Figure 6: Number of Products under Development by Companies Insomnia
  • Figure 7: Number of Products under Development by Universities/Institutes Insomnia
  • Figure 8: Number of Products by Targets Restless Legs Syndrome
  • Figure 9: Number of Products by Stage and Targets Restless Legs Syndrome
  • Figure 10: Number of Products by Mechanism of Actions Restless Legs Syndrome
  • Figure 11: Number of Products by Stage and Mechanism of Actions Restless Legs Syndrome
  • Figure 12: Number of Products by Routes of Administration Restless Legs Syndrome
  • Figure 13: Number of Products by Stage and Routes of Administration Restless Legs Syndrome
  • Figure 14: Number of Products by Molecule Types Restless Legs Syndrome
  • Figure 15: Number of Products by Stage and Molecule Types Restless Legs Syndrome
  • Figure 16: Number of Products by Targets Nocturia
  • Figure 17: Number of Products by Stage and Targets Nocturia
  • Figure 18: Number of Products by Mechanism of Actions Nocturia
  • Figure 19: Number of Products by Stage and Mechanism of Actions Nocturia
  • Figure 20: Number of Products by Routes of Administration Nocturia
  • Figure 21: Number of Products by Stage and Routes of Administration Nocturia
  • Figure 22: Number of Products by Molecule Types Nocturia
  • Figure 23: Number of Products by Stage and Molecule Types Nocturia
  • Figure 24: Number of Products by Top 10 Targets Insomnia
  • Figure 25: Number of Products by Stage and Top 10 Targets Insomnia
  • Figure 26: Number of Products by Top 10 Mechanism of Actions Insomnia
  • Figure 27: Number of Products by Stage and Top 10 Mechanism of Actions Insomnia
  • Figure 28: Number of Products by Routes of Administration Insomnia
  • Figure 29: Number of Products by Stage and Routes of Administration Insomnia
  • Figure 30: Number of Products by Stage and Molecule Types Insomnia